The therapeutic effect of five agents: sulfamethoxazole-trimethoprim (ST), minocycline (MINO), cefmenoxime (CMX), streptomycin (SM) and amikacin (AMK) and fourthree-drug-regimens: kanamycin (KM) rif ampicin (RFP)-ethambutol (EB), KM-CMXMINO, KM-RFP-ST and MINO-leucomycin (LM)-sulfadimethoxine were evaluated invivo for ddY or BALB/c mice infected intravenously with Mycobacterium avium-intracellulare, 31F093T strain.These drugs were all administered to the animals five daysa week in dosages roughly comparable with clinical use from 1 wk of infection.Themacroscopic lesions, the weights of organs and the counts of viable bacilli in lungs, spleenand kidneys were observed every three weeks during treatment (9 weeks).
KM and AMK (both in single use), and three three-drug-regimens (KM-RFP-EB, KM-CMX-MINO and KM-RFP-ST) exerted suppresive effect of macroscopic lesions andviable count of bacilli in the lungs.However, MINO, CMX and SM (all in single use) anda three-drug-regimen: MINO-LM-sulfadimethoxine demonstrated only slight tendancy ofsuppresion of macroscopic diseases and viable counts of bacilli in the lungs.Observationsof viable counts of bacilli in spleeen and kidneys showed almost the same tendencies.
In these experiments, AMK that was one of aminoglycosides had the same therapeuticeffect as KM on murine M.avium-intracellulare infection.And CMX, MINO and ST couldalso exerted therapeutic effect if they were used as a combined drug in multiple-drugregimens.These drugs might be taken into consideration in the therapy of human M.avium-intracellulare infection.
View full abstract